Breakthroughs in Pulmonary Disease, Advancements in PE Management at CHEST 2024

The CHEST 2024 annual meeting brought together over 6000 to 8000 pulmonologists and researchers to share cutting-edge developments in pulmonary disease, pulmonary embolism (PE), and pulmonary hypertension. One of the key highlights was the discussion of Pulmonary Embolism Response Teams (PERT), addressing controversies in PE management and focusing on personalized, patient-centered care.

Parth Rali, MD, and Krunal Patel, MD from Temple University, emphasized the importance of tailoring treatment based on individual needs with a close look at recent clinical trials in both pulmonary hypertension and PE.

Clinical trials were another recurring theme throughout the conference. Presentations reviewed lessons learned from recent years across pulmonary conditions such as pulmonary vascular disease and explored both positive and negative trial outcomes, setting the stage for advancements in the 2 few years. For institutions like Temple Lung Center, there is a strong push to increase clinical trial participation and bring innovative treatments to more patients.

Beyond pulmonary vascular disease, chronic obstructive pulmonary disease (COPD) emerged as a significant focus, with discussions on the future of its treatment. After decades of relying on inhaler therapies, Jonathan Kurman, MD, Medical College of Wisconsin, Froedtert Hospital, showcased new pharmacologic and nonpharmacologic interventions that promise to transform the standard of care for patients with COPD. Biologics and precision medicine are expected to play a crucial role, offering more personalized treatment options based on patients’ phenotypes and genotypes.

In addition to major disease advancements, Zeina Morcors, MD, Staten Island University Hospital, praised the tailored learning opportunities provided. Sessions on sepsis, pregnancy-related embolism, and asthma offered practical knowledge to apply in daily hospital settings. The event also featured simulation experiences, case report presentations, and interactive discussions with global experts.

Sleep medicine also gained attention at CHEST 2024. Tetyana Kendzerska, MD, Division of Respirology, University of Ottawa, presented new research on the relationship between sleep-disordered breathing and mental health conditions, particularly among marginalized populations. She highlighted gaps in sleep study follow-up care, especially for inpatients, and emphasized the need to improve access to sleep therapy.

A final critical takeaway from the conference was the acknowledgment of racial disparities in pulmonary care, brought to light by data presented by Cesar Davila-Chapa, MD, University of Nebraska Medical Center. These inequities continue to affect patient outcomes and hospitalizations, underscoring the importance of addressing social determinants of health in future research and clinical practice.

The CHEST 2024 annual meeting successfully bridged past, present, and future advancements, providing valuable insights and shaping the future of pulmonary care.